90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

Purpose: B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, 90Y-labeled ibritumomab tiuxetan (90YIT) in B-cell NHLs. Methods and Materials...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Zsolt Szakács, MD, PhD, Amar Lal, MD, Jorgen Kristensen, MD, PhD, Nelli Farkas, PhD, Zsombor Ritter, MD, Szabolcs Kiss, MD, Hussain Alizadeh, MD, PhD, Anett Balikó, MD
التنسيق: مقال
اللغة:English
منشور في: Elsevier 2022-09-01
سلاسل:Advances in Radiation Oncology
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S2452109421002402

الانترنت

http://www.sciencedirect.com/science/article/pii/S2452109421002402

مواد مشابهة